All In Biotech

Investigational drug · Phase 2

SYH2072

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uncontrolled Hypertension, Resistant Hypertension, Primary Aldosteronism.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "SYH2072"

First trial start

2026

Nov 13, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SYH2072", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Uncontrolled Hypertension
  • Resistant Hypertension
  • Primary Aldosteronism

Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "SYH2072" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Uncontrolled Hypertension

  • SAL0120Phase 32 trials

    Shenzhen Salubris Pharmaceuticals Co., Ltd. · Chronic Kidney Disease, Uncontrolled Hypertension, Resistant Hypertension

  • SAL0140Phase 23 trials

    Shenzhen Salubris Pharmaceuticals Co., Ltd. · Primary Aldosteronism, Chronic Kidney Disease, Uncontrolled Hypertension

  • of QLS1410Phase 22 trials

    Qilu Pharmaceutical Co., Ltd. · Hypertension (HTN), Uncontrolled Hypertension

  • RTN-001SLx-2101Phase 21 trial

    Retension Pharmaceuticals. Inc. · Uncontrolled Hypertension

  • VB19055Phase 21 trial

    Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · Hypertension, Resistant Hypertension, Uncontrolled Hypertension

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.